Regenxbio IncNASDAQ:RGNX
- LAST PRICE14.3300
- TODAY'S CHANGE (%)-0.0600 (-0.4170%)
- Bid / Lots14.0000/ 1
- Ask / Lots15.5500/ 5
- Open / Previous Close14.7600 / 14.3900
- Day Range
- 52 Week Range
- Volume318,487
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | RGNX |
|---|---|---|
| 09:32 ET | 4651 | 14.48 |
| 09:34 ET | 600 | 14.53 |
| 09:38 ET | 2800 | 14.5 |
| 09:39 ET | 1027 | 14.5384 |
| 09:41 ET | 2471 | 14.53 |
| 09:43 ET | 2979 | 14.52 |
| 09:45 ET | 4042 | 14.5 |
| 09:48 ET | 6700 | 14.54 |
| 09:50 ET | 2305 | 14.55 |
| 09:52 ET | 3600 | 14.5 |
| 09:54 ET | 625 | 14.485 |
| 09:56 ET | 4061 | 14.49 |
| 09:57 ET | 700 | 14.53 |
| 09:59 ET | 1178 | 14.625 |
| 10:01 ET | 1268 | 14.75 |
| 10:03 ET | 800 | 14.755 |
| 10:08 ET | 667 | 14.67 |
| 10:10 ET | 400 | 14.57 |
| 10:12 ET | 200 | 14.575 |
| 10:14 ET | 109 | 14.57 |
| 10:15 ET | 2800 | 14.51 |
| 10:17 ET | 300 | 14.555 |
| 10:19 ET | 300 | 14.5 |
| 10:21 ET | 910 | 14.44 |
| 10:24 ET | 100 | 14.45 |
| 10:26 ET | 600 | 14.455 |
| 10:28 ET | 100 | 14.435 |
| 10:30 ET | 2100 | 14.42 |
| 10:32 ET | 1118 | 14.215 |
| 10:33 ET | 1079 | 14.275 |
| 10:35 ET | 854 | 14.289 |
| 10:39 ET | 512 | 14.4 |
| 10:42 ET | 100 | 14.45 |
| 10:46 ET | 1100 | 14.45 |
| 10:48 ET | 3194 | 14.4915 |
| 10:51 ET | 1200 | 14.43 |
| 10:53 ET | 1292 | 14.48 |
| 10:55 ET | 100 | 14.52 |
| 10:57 ET | 924 | 14.52 |
| 11:00 ET | 1600 | 14.5 |
| 11:02 ET | 100 | 14.52 |
| 11:04 ET | 1100 | 14.425 |
| 11:06 ET | 1419 | 14.33 |
| 11:08 ET | 340 | 14.3004 |
| 11:13 ET | 470 | 14.34 |
| 11:15 ET | 400 | 14.3483 |
| 11:18 ET | 300 | 14.3 |
| 11:20 ET | 300 | 14.26 |
| 11:22 ET | 100 | 14.295 |
| 11:24 ET | 200 | 14.29 |
| 11:26 ET | 1300 | 14.27 |
| 11:27 ET | 421 | 14.2201 |
| 11:29 ET | 100 | 14.26 |
| 11:31 ET | 333 | 14.23 |
| 11:33 ET | 100 | 14.26 |
| 11:38 ET | 1700 | 14.31 |
| 11:42 ET | 975 | 14.31 |
| 11:44 ET | 200 | 14.35 |
| 11:47 ET | 600 | 14.3 |
| 11:49 ET | 100 | 14.2601 |
| 11:54 ET | 500 | 14.31 |
| 11:56 ET | 545 | 14.26 |
| 12:00 ET | 900 | 14.25 |
| 12:02 ET | 600 | 14.28 |
| 12:05 ET | 100 | 14.28 |
| 12:07 ET | 200 | 14.29 |
| 12:09 ET | 200 | 14.32 |
| 12:12 ET | 472 | 14.34 |
| 12:14 ET | 250 | 14.3107 |
| 12:16 ET | 100 | 14.33 |
| 12:18 ET | 300 | 14.29 |
| 12:20 ET | 100 | 14.28 |
| 12:21 ET | 400 | 14.27 |
| 12:23 ET | 200 | 14.205 |
| 12:25 ET | 400 | 14.22 |
| 12:27 ET | 100 | 14.23 |
| 12:30 ET | 100 | 14.2 |
| 12:32 ET | 200 | 14.21 |
| 12:34 ET | 100 | 14.2 |
| 12:36 ET | 2420 | 14.24 |
| 12:38 ET | 400 | 14.24 |
| 12:43 ET | 917 | 14.26 |
| 12:45 ET | 500 | 14.245 |
| 12:48 ET | 100 | 14.24 |
| 12:50 ET | 200 | 14.245 |
| 12:52 ET | 619 | 14.22 |
| 12:54 ET | 300 | 14.205 |
| 12:56 ET | 100 | 14.205 |
| 12:59 ET | 1400 | 14.23 |
| 01:01 ET | 200 | 14.24 |
| 01:06 ET | 304 | 14.21 |
| 01:08 ET | 684 | 14.23 |
| 01:14 ET | 200 | 14.23 |
| 01:15 ET | 420 | 14.21 |
| 01:17 ET | 1100 | 14.17 |
| 01:19 ET | 100 | 14.16 |
| 01:21 ET | 400 | 14.195 |
| 01:24 ET | 100 | 14.18 |
| 01:26 ET | 100 | 14.205 |
| 01:28 ET | 100 | 14.205 |
| 01:30 ET | 1623 | 14.23 |
| 01:32 ET | 550 | 14.2 |
| 01:35 ET | 455 | 14.19 |
| 01:37 ET | 100 | 14.19 |
| 01:42 ET | 700 | 14.24 |
| 01:46 ET | 100 | 14.265 |
| 01:48 ET | 450 | 14.3 |
| 01:55 ET | 100 | 14.36 |
| 01:57 ET | 100 | 14.32 |
| 02:04 ET | 2144 | 14.34 |
| 02:06 ET | 500 | 14.325 |
| 02:11 ET | 100 | 14.325 |
| 02:15 ET | 200 | 14.33 |
| 02:20 ET | 200 | 14.3315 |
| 02:22 ET | 300 | 14.27 |
| 02:24 ET | 200 | 14.27 |
| 02:26 ET | 500 | 14.26 |
| 02:27 ET | 300 | 14.24 |
| 02:31 ET | 500 | 14.21 |
| 02:33 ET | 400 | 14.22 |
| 02:36 ET | 400 | 14.22 |
| 02:38 ET | 200 | 14.23 |
| 02:42 ET | 100 | 14.21 |
| 02:45 ET | 208 | 14.19 |
| 02:47 ET | 1200 | 14.19 |
| 02:49 ET | 1211 | 14.21 |
| 02:51 ET | 200 | 14.205 |
| 02:54 ET | 1000 | 14.21 |
| 02:56 ET | 300 | 14.22 |
| 02:58 ET | 100 | 14.26 |
| 03:00 ET | 100 | 14.25 |
| 03:02 ET | 551 | 14.25 |
| 03:03 ET | 100 | 14.24 |
| 03:05 ET | 621 | 14.245 |
| 03:09 ET | 700 | 14.255 |
| 03:12 ET | 1337 | 14.35 |
| 03:14 ET | 510 | 14.35 |
| 03:16 ET | 300 | 14.31 |
| 03:20 ET | 100 | 14.31 |
| 03:21 ET | 100 | 14.3 |
| 03:23 ET | 625 | 14.35 |
| 03:25 ET | 2022 | 14.355 |
| 03:27 ET | 400 | 14.35 |
| 03:32 ET | 100 | 14.33 |
| 03:34 ET | 400 | 14.32 |
| 03:36 ET | 2400 | 14.305 |
| 03:38 ET | 600 | 14.3 |
| 03:39 ET | 2928 | 14.37 |
| 03:41 ET | 900 | 14.36 |
| 03:43 ET | 523 | 14.34 |
| 03:45 ET | 1230 | 14.365 |
| 03:48 ET | 400 | 14.36 |
| 03:50 ET | 1837 | 14.38 |
| 03:52 ET | 6327 | 14.37 |
| 03:54 ET | 3013 | 14.34 |
| 03:56 ET | 5077 | 14.31 |
| 03:57 ET | 4445 | 14.33 |
| 03:59 ET | 7859 | 14.33 |
Yesterday
REGENXBIO to Host Conference Call on August 1 to Discuss Second Quarter 2024 Financial Results and Recent Operational Highlights, from 7:05AM ET on Thursday Jul 25, 2024 by Dow Jones
7:05AM ET on Thursday Jul 25, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Regenxbio Inc | 708.8M | -2.4x | --- |
Urogen Pharma Ltd | 673.5M | -4.8x | --- |
SAGE Therapeutics Inc | 630.1M | -1.3x | --- |
Alector Inc | 625.5M | -4.7x | --- |
Zymeworks Inc | 751.6M | -6.0x | --- |
Y-mAbs Therapeutics Inc | 541.1M | -25.3x | --- |
Company Information
REGENXBIO Inc. is a clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. The Company has developed a pipeline of gene therapy programs using its proprietary adeno-associated virus (AAV) gene therapy delivery platform (NAV Technology Platform) to address genetic diseases. The Company is focused on its internal development pipeline in three areas: retinal, neuromuscular and neurodegenerative diseases. Its investigational AAV therapeutics include ABBV-RGX-314, RGX-202 and RGX-121. It is developing ABBV-RGX-314 in collaboration with AbbVie to treat large patient populations impacted by wet age-related macular degeneration, diabetic retinopathy (DR) and other chronic retinal diseases characterized by loss of vision. It is developing RGX-202 to treat Duchenne muscular dystrophy (Duchenne). The Company is developing RGX-121 to treat Mucopolysaccharidosis type II (MPS II), a progressive, neurodegenerative lysosomal storage disorder.
Contact Information
- Headquarters
- 9804 Medical Center DriveROCKVILLE, MD, United States 20850
- Phone
- 240-552-8181
- Fax
- 302-655-5049
Executives
- Chairman of the Board
- Kenneth Mills
- President, Chief Executive Officer, Director
- Curran Simpson
- Chief Financial Officer, Executive Vice President
- Vittal Vasista
- Executive Vice President, Chief Scientific Officer
- Olivier Danos
- Executive Vice President, Chief Legal Officer
- Patrick Christmas
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $708.8M |
|---|---|
Revenue (TTM) | $86.7M |
Shares Outstanding | 49.3M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.23 |
EPS | $-5.88 |
Book Value | $7.08 |
P/E Ratio | -2.4x |
Price/Sales (TTM) | 8.2 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -306.52% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
